BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Incyte readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Incyte's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06843408-3003@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT06843408)
DESCRIPTION:Axatilimab\, phase 1/2\, Chronic Graft-versus-Host Disease.\nSt
 udy: A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With
  Recurrent or Refractory cGVHD\nEstimated primary completion: 6 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06843408
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023627-10796@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:INCB123667: Phase 2 readout est. (NCT07023627)
DESCRIPTION:INCB123667\, phase 2\, Ovarian Cancer.\nStudy: A Study of INCB1
 23667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E
 1 Overexpression\nEstimated primary completion: 27 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/incb123667#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07023627
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804811-11030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06804811)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to <
  12 Years Old) With Nonsegmental Vitiligo\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolit
 inib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06804811
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03040973-1968@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Capmatinib: Phase 2 readout est. (NCT03040973)
DESCRIPTION:Capmatinib\, phase 2.\nStudy: Study to Allow Patients Previousl
 y Participating in a Novartis Sponsored Trial to Continue Receiving Capmat
 inib Treatment as Single Agent or in Combination With Other Treatments or 
 the Combination Treatment Alone\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capmatinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03040973
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465433-5647@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270829
DTEND;VALUE=DATE:20270830
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06465433)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Extension Study to Provide Conti
 nued Treatment for Patients With Hematologic Malignancies Previously Enrol
 led in Studies With Tafasitamab\nEstimated primary completion: 29 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06465433
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104565-5647@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07104565)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Study to Assess the Safety and T
 olerability of Tafasitamab in Adult Participants With Primary Autoimmune B
 lood Cell Disorders\nEstimated primary completion: 23 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07104565
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585774-3003@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06585774)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment
  for Chronic Graft-Versus-Host Disease\nEstimated primary completion: 28 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axatil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06585774
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-7619@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02955940)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: An Open-Label Study to 
 Enable Continued Treatment Access for Subjects Previously Enrolled in Stud
 ies of Ruxolitinib\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02955940
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214779-10796@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:INCB123667: Phase 3 readout est. (NCT07214779)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Study to Evaluat
 e INCB123667 Versus Investigator's Choice of Chemotherapy in Participants 
 With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression\nEsti
 mated primary completion: 12 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/incb123667#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07214779
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03934372-10794@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT03934372)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Chronic Myeloid Leukemia.\nSt
 udy: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent
  or Refractory Leukemias\, Lymphomas or Solid Tumors\nEstimated primary co
 mpletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03934372
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05723198-98@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT05723198)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Alopecia Areata.\nStudy: A S
 tudy of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Y
 ears of Age With Alopecia Areata\nEstimated primary completion: March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05723198
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821542-3003@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06821542)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Partici
 pants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines 
 of Systemic Therapy\nEstimated primary completion: 31 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06821542
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548360-11030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06548360)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Partic
 ipants With Nonsegmental Vitiligo\nEstimated primary completion: 5 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzel
 ura#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06548360
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222332-98@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07222332)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly 
 Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ba
 ricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07222332
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-5647@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tafasitamab: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Tafasitamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combin
 ation With Gemcitabine and Oxaliplatin Versus Rituximab in Combination Wit
 h Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse
  Large B-Cell Lymphoma\nEstimated primary completion: September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522073-2548@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:INCB161734: Phase 3 readout est. (NCT07522073)
DESCRIPTION:INCB161734\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStudy
 : A Study to Evaluate Chemotherapy With or Without INCB161734 in Previousl
 y Untreated\, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinom
 a\nEstimated primary completion: 15 September 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/incb161734#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07522073
URL:https://assetmemo.bio/drug/incb161734#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284849-2547@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:INCA33890: Phase 3 readout est. (NCT07284849)
DESCRIPTION:INCA33890\, phase 3\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevaciz
 umab With or Without INCA33890 in the First-Line Treatment of Metastatic M
 icrosatellite Stable Colorectal Cancer\nEstimated primary completion: 29 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inca338
 90#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7284849
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124078-3003@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07124078)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatr
 ic Participants With Chronic Graft-Versus-Host Disease After at Least 2 Pr
 ior Lines of Systemic Therapy (AGAVE-256)\nEstimated primary completion: 3
 1 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axati
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07124078
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823322-2547@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:INCA33890: Phase 2 readout est. (NCT07823322)
DESCRIPTION:INCA33890\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage I
 I/III Microsatellite Stable Colorectal Cancer After Curative Resection and
  Chemotherapy\nEstimated primary completion: 14 May 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/inca33890#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07823322
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623200-10795@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:INCA033989: Phase 3 readout est. (NCT07623200)
DESCRIPTION:INCA033989\, phase 3\, Essential Thrombocythemia.\nStudy: A Pha
 se 3 Study of INCA033989 Versus Best Available Therapy in Participants Wit
 h Essential Thrombocythemia\nEstimated primary completion: 15 June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/inca033989#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07623200
URL:https://assetmemo.bio/drug/inca033989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401356-7619@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06401356)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3.\nStudy: An Extension Study for 
 Patients Previously Enrolled in Studies With Pelabresib\nEstimated primary
  completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06401356
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615050-7619@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06615050)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3\, Graft-versus-Host Disease.\nSt
 udy: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant
  Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Re
 duced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transpl
 antation (BMT CTN 2203)\nEstimated primary completion: 17 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06615050
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862998-2225@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310225
DTEND;VALUE=DATE:20310226
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07862998)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants
  With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Wi
 th FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic 
 Therapy\nEstimated primary completion: 25 February 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07862998
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03773965-98@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT03773965)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idio
 pathic Arthritis\nEstimated primary completion: July 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03773965
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222137-98@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07222137)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children
  and Adults\nEstimated primary completion: July 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07222137
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797283-10796@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20320501
DTEND;VALUE=DATE:20320502
SUMMARY:INCB123667: Phase 3 readout est. (NCT07797283)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Study of
  INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Mainte
 nance Therapy in Ovarian Cancer Overexpressing Cyclin E1\nEstimated primar
 y completion: 1 May 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/incb123667#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07797283
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
